Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Revisiting NTRKs as an emerging oncogene in hematological malignancies.

Joshi SK, Davare MA, Druker BJ, Tognon CE.

Leukemia. 2019 Sep 24. doi: 10.1038/s41375-019-0576-8. [Epub ahead of print] Review.

PMID:
31551508
2.

A ribose modification of Spinach aptamer accelerates lead(ii) cation association in vitro.

Savage JC, Shinde P, B├Ąchinger HP, Davare MA, Shinde U.

Chem Commun (Camb). 2019 May 25;55(42):5882-5885. doi: 10.1039/c9cc01697j. Epub 2019 Apr 30.

PMID:
31037281
3.

A blast from the past: ROS1 on the brain.

Odintsov I, Somwar R, Davare MA.

Oncotarget. 2019 Mar 1;10(18):1664-1666. doi: 10.18632/oncotarget.26752. eCollection 2019 Mar 1. No abstract available.

4.

Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.

Davis LE, Nusser KD, Przybyl J, Pittsenbarger J, Hofmann NE, Varma S, Vennam S, Debiec-Rychter M, van de Rijn M, Davare MA.

Mol Cancer Res. 2019 Mar;17(3):676-685. doi: 10.1158/1541-7786.MCR-18-1075. Epub 2018 Dec 5. Erratum in: Mol Cancer Res. 2019 Sep;17(9):1958.

PMID:
30518629
5.

Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.

Davare MA, Henderson JJ, Agarwal A, Wagner JP, Iyer SR, Shah N, Woltjer R, Somwar R, Gilheeney SW, DeCarvalo A, Mikkelson T, Van Meir EG, Ladanyi M, Druker BJ.

Clin Cancer Res. 2018 Dec 15;24(24):6471-6482. doi: 10.1158/1078-0432.CCR-18-1052. Epub 2018 Aug 31.

PMID:
30171048
6.

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.

Hosseini MM, Kurtz SE, Abdelhamed S, Mahmood S, Davare MA, Kaempf A, Elferich J, McDermott JE, Liu T, Payne SH, Shinde U, Rodland KD, Mori M, Druker BJ, Singer JW, Agarwal A.

Leukemia. 2018 Nov;32(11):2374-2387. doi: 10.1038/s41375-018-0112-2. Epub 2018 Mar 29.

7.

Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line.

Henderson JJ, Wagner JP, Hofmann NE, Eide CA, Cho YJ, Druker BJ, Davare MA.

Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26553. Epub 2017 Apr 14.

PMID:
28409891
8.

IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma.

Svalina MN, Kikuchi K, Abraham J, Lal S, Davare MA, Settelmeyer TP, Young MC, Peckham JL, Cho YJ, Michalek JE, Hernandez BS, Berlow NE, Jackson M, Guillaume DJ, Selden NR, Bigner DD, Nazemi KJ, Green SC, Corless CL, Gultekin S, Mansoor A, Rubin BP, Woltjer R, Keller C.

Sci Rep. 2016 Jun 3;6:27012. doi: 10.1038/srep27012.

9.

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.

Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, Arcila ME, Hechtman JF, Wang L, Smith RS, Kris MG, Riely GJ, Druker BJ, O'Hare T, Ladanyi M, Davare MA.

Clin Cancer Res. 2016 May 15;22(10):2351-8. doi: 10.1158/1078-0432.CCR-15-2013. Epub 2015 Dec 16.

10.

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.

Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, Deininger MW, O'Hare T, Druker BJ.

Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):E5381-90. doi: 10.1073/pnas.1515281112. Epub 2015 Sep 8.

11.

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.

Siegel MB, Liu SQ, Davare MA, Spurgeon SE, Loriaux MM, Druker BJ, Scott EC, Tyner JW.

Oncotarget. 2015 Aug 7;6(22):18921-32.

12.

Therapeutically Targetable ALK Mutations in Leukemia.

Maxson JE, Davare MA, Luty SB, Eide CA, Chang BH, Loriaux MM, Tognon CE, Bottomly D, Wilmot B, McWeeney SK, Druker BJ, Tyner JW.

Cancer Res. 2015 Jun 1;75(11):2146-50. doi: 10.1158/0008-5472.CAN-14-1576.

13.

Detecting and targetting oncogenic fusion proteins in the genomic era.

Davare MA, Tognon CE.

Biol Cell. 2015 May;107(5):111-29. doi: 10.1111/boc.201400096. Epub 2015 Apr 7. Review.

14.

Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.

Agarwal A, MacKenzie RJ, Eide CA, Davare MA, Watanabe-Smith K, Tognon CE, Mongoue-Tchokote S, Park B, Braziel RM, Tyner JW, Druker BJ.

Oncogene. 2015 Jun 4;34(23):2991-9. doi: 10.1038/onc.2014.243. Epub 2014 Aug 11.

15.

Leptin-induced spine formation requires TrpC channels and the CaM kinase cascade in the hippocampus.

Dhar M, Wayman GA, Zhu M, Lambert TJ, Davare MA, Appleyard SM.

J Neurosci. 2014 Jul 23;34(30):10022-33. doi: 10.1523/JNEUROSCI.2868-13.2014.

16.

Secreted meningeal chemokines, but not VEGFA, modulate the migratory properties of medulloblastoma cells.

Davare MA, Lal S, Peckham JL, Prajapati SI, Gultekin SH, Rubin BP, Keller C.

Biochem Biophys Res Commun. 2014 Jul 18;450(1):555-60. doi: 10.1016/j.bbrc.2014.06.018. Epub 2014 Jun 10.

17.

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.

Davare MA, Saborowski A, Eide CA, Tognon C, Smith RL, Elferich J, Agarwal A, Tyner JW, Shinde UP, Lowe SW, Druker BJ.

Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19519-24. doi: 10.1073/pnas.1319583110. Epub 2013 Nov 11.

18.

Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target.

Saborowski A, Saborowski M, Davare MA, Druker BJ, Klimstra DS, Lowe SW.

Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19513-8. doi: 10.1073/pnas.1311707110. Epub 2013 Oct 23.

19.

Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model.

Ohshima-Hosoyama S, Davare MA, Prajapati SI, Abraham J, Lal S, Nelon LD, Kilcoyne A, Giles FJ, Hanes MA, Rubin BP, Keller C.

J Pediatr Hematol Oncol. 2012 Mar;34(2):116-21. doi: 10.1097/MPH.0b013e3182309fe4.

20.

Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma.

Ohshima-Hosoyama S, Davare MA, Hosoyama T, Nelon LD, Keller C.

J Neurooncol. 2011 Dec;105(3):475-83. doi: 10.1007/s11060-011-0619-0. Epub 2011 Jun 3.

PMID:
21633906
21.

Analysis of CaM-kinase signaling in cells.

Wayman GA, Tokumitsu H, Davare MA, Soderling TR.

Cell Calcium. 2011 Jul;50(1):1-8. doi: 10.1016/j.ceca.2011.02.007. Epub 2011 Apr 29. Review.

22.

Calmodulin-kinases regulate basal and estrogen stimulated medulloblastoma migration via Rac1.

Davare MA, Saneyoshi T, Soderling TR.

J Neurooncol. 2011 Aug;104(1):65-82. doi: 10.1007/s11060-010-0472-6. Epub 2010 Nov 24.

PMID:
21107644
23.

Long-term potentiation-dependent spine enlargement requires synaptic Ca2+-permeable AMPA receptors recruited by CaM-kinase I.

Fortin DA, Davare MA, Srivastava T, Brady JD, Nygaard S, Derkach VA, Soderling TR.

J Neurosci. 2010 Sep 1;30(35):11565-75. doi: 10.1523/JNEUROSCI.1746-10.2010.

24.

ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells.

Schmitt JM, Abell E, Wagner A, Davare MA.

Mol Cell Biochem. 2010 Feb;335(1-2):155-71. doi: 10.1007/s11010-009-0252-9. Epub 2009 Sep 18.

PMID:
19763792
25.

Transient receptor potential canonical 5 channels activate Ca2+/calmodulin kinase Igamma to promote axon formation in hippocampal neurons.

Davare MA, Fortin DA, Saneyoshi T, Nygaard S, Kaech S, Banker G, Soderling TR, Wayman GA.

J Neurosci. 2009 Aug 5;29(31):9794-808. doi: 10.1523/JNEUROSCI.1544-09.2009.

26.

Statins decrease dendritic arborization in rat sympathetic neurons by blocking RhoA activation.

Kim WY, Gonsiorek EA, Barnhart C, Davare MA, Engebose AJ, Lauridsen H, Bruun D, Lesiak A, Wayman G, Bucelli R, Higgins D, Lein PJ.

J Neurochem. 2009 Feb;108(4):1057-71.

27.

Critical role of cAMP-dependent protein kinase anchoring to the L-type calcium channel Cav1.2 via A-kinase anchor protein 150 in neurons.

Hall DD, Davare MA, Shi M, Allen ML, Weisenhaus M, McKnight GS, Hell JW.

Biochemistry. 2007 Feb 13;46(6):1635-46. Epub 2007 Jan 20.

PMID:
17279627
29.

Inhibition of calcium/calmodulin-dependent protein kinase kinase by protein 14-3-3.

Davare MA, Saneyoshi T, Guire ES, Nygaard SC, Soderling TR.

J Biol Chem. 2004 Dec 10;279(50):52191-9. Epub 2004 Oct 6.

30.

Increased phosphorylation of the neuronal L-type Ca(2+) channel Ca(v)1.2 during aging.

Davare MA, Hell JW.

Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):16018-23. Epub 2003 Dec 9.

31.

Follicle-stimulating hormone activates extracellular signal-regulated kinase but not extracellular signal-regulated kinase kinase through a 100-kDa phosphotyrosine phosphatase.

Cottom J, Salvador LM, Maizels ET, Reierstad S, Park Y, Carr DW, Davare MA, Hell JW, Palmer SS, Dent P, Kawakatsu H, Ogata M, Hunzicker-Dunn M.

J Biol Chem. 2003 Feb 28;278(9):7167-79. Epub 2002 Dec 18.

32.

A beta2 adrenergic receptor signaling complex assembled with the Ca2+ channel Cav1.2.

Davare MA, Avdonin V, Hall DD, Peden EM, Burette A, Weinberg RJ, Horne MC, Hoshi T, Hell JW.

Science. 2001 Jul 6;293(5527):98-101. Erratum in: Science 2001 Aug 3;293(5531):804.

33.

SAP97 concentrates at the postsynaptic density in cerebral cortex.

Valtschanoff JG, Burette A, Davare MA, Leonard AS, Hell JW, Weinberg RJ.

Eur J Neurosci. 2000 Oct;12(10):3605-14.

PMID:
11029631
35.
36.

SAP97 is associated with the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR1 subunit.

Leonard AS, Davare MA, Horne MC, Garner CC, Hell JW.

J Biol Chem. 1998 Jul 31;273(31):19518-24.

Supplemental Content

Loading ...
Support Center